Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pemafibrate for Symptomatic ICAS RCT (PPAR-ICAS)

30. juli 2026 oppdatert av: Kenichi Todo, Tokyo Women's Medical University

Triglyceride-lowering Therapy With Pemafibrate for Prevention of Atherosclerotic Cardiovascular Disease in Patients With Symptomatic Intracranial Artery Stenosis: a Multi-center, Open-label, Randomized Controlled Trial (PPAR-ICAS)

The goal of this clinical trial is to learn whether pemafibrate can help prevent worsening of intracranial arterial stenosis (ICAS) in patients who have symptomatic ICAS and high triglycerides (TG) levels after ischemic stroke or transient ischemic attack (TIA).

The main questions this study aims to answer are:

  1. Does pemafibrate lower the chance that ICAS gets worse over 12 months?
  2. Does pemafibrate improve TG levels and other vascular risk markers?
  3. What are the effects of pemafibrate on vascular events, functional outcomes, and safety over 12 months?

Researchers will compare a pemafibrate group with a non-pemafibrate group to see whether pemafibrate helps prevent progression of ICAS. This is an open-label, randomized, parallel-group trial. That means participants are assigned by chance to 1 of 2 groups, and both the researchers and participants know which group was assigned. Participants in both groups will continue to receive standard stroke care, including antithrombotic therapy and management of vascular risk factors such as blood pressure, low-density lipoprotein cholesterol, diabetes, and smoking.

Participants may be eligible if they are 18 years or older, have clinically stable ischemic stroke or TIA, have 50% to 99% stenosis in a symptomatic intracranial artery on contrast-enhanced CT angiography (CTA), and have elevated fasting (>=150 mg/dL) or non-fasting (>=175 mg/dL) TG levels. Some people will not be eligible, such as those with ICAS due to non-atherosclerotic arterial disease, severe extracranial carotid stenosis, recent intravenous thrombolysis or mechanical thrombectomy, planned revascularization, contraindications to pemafibrate or iodinated contrast media, dialysis, or pregnancy.

Participants will:

  • Be randomly assigned to a pemafibrate group or a non-pemafibrate group
  • Take pemafibrate for 12 months if assigned to the pemafibrate group, with possible dose adjustment based on TG levels and kidney function
  • Have blood tests and clinical assessments at baseline and during follow-up
  • Undergo brain CTA at study entry and again at 12 months
  • Undergo brain MRI/MRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity according to the study schedule
  • Be followed for vascular events, functional outcome, and adverse events for 1 year

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

270

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Japan
    • Aichi-ken
      • Toyoake, Aichi-ken, Japan, 470-1192
        • Har ikke rekruttert ennå
        • Fujita Health University Hospital
        • Ta kontakt med:
    • Chiba
      • Yachiyo, Chiba, Japan, 276-8524
        • Har ikke rekruttert ennå
        • Tokyo Women's Medical University Yachiyo Medical Center
        • Ta kontakt med:
    • Hiroshima
      • Fukuyama, Hiroshima, Japan, 720-0825
        • Har ikke rekruttert ennå
        • Brain Attack Center Ota Memorial Hospital
        • Ta kontakt med:
      • Hiroshima, Hiroshima, Japan, 730-8518
        • Har ikke rekruttert ennå
        • Hiroshima City Hiroshima Citizens Hospital
        • Ta kontakt med:
    • Hyōgo
      • Kobe, Hyōgo, Japan, 650-0047
        • Har ikke rekruttert ennå
        • Kobe City Medical Center General Hospital
        • Ta kontakt med:
    • Ibaraki
      • Tsukuba, Ibaraki, Japan, 305-8576
        • Har ikke rekruttert ennå
        • University of Tsukuba Hospital
        • Ta kontakt med:
    • Iwate
      • Hizume, Iwate, Japan, 028-3695
        • Rekruttering
        • Iwate Medical University Hospital
        • Ta kontakt med:
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 892-0853
        • Rekruttering
        • Kagoshima Medical Center
        • Ta kontakt med:
    • Kanagawa
      • Isehara, Kanagawa, Japan, 259-1193
        • Har ikke rekruttert ennå
        • Tokai University Hopital
        • Ta kontakt med:
      • Kawasaki, Kanagawa, Japan, 211-8533
        • Har ikke rekruttert ennå
        • Nippon Medical School Musashikosugi Hospital
        • Ta kontakt med:
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 860-8556
    • Kyoto
      • Kyoto, Kyoto, Japan, 602-8566
        • Rekruttering
        • University Hospital Kyoto Prefectural University of Medicine
        • Ta kontakt med:
      • Kyoto, Kyoto, Japan, 602-8026
        • Rekruttering
        • Japanese Red Cross Kyoto Daini Hospital
        • Ta kontakt med:
    • Nagasaki
      • Nagasaki, Nagasaki, Japan, 852-8501
        • Rekruttering
        • Nagasaki University Hospital
        • Ta kontakt med:
    • Okayama-ken
      • Kurashiki, Okayama-ken, Japan, 701-0192
        • Rekruttering
        • Kawasaki Medical School Hospital
        • Ta kontakt med:
    • Osaka
      • Hirakata, Osaka, Japan, 573-1191
        • Rekruttering
        • Kansai Medical University Hospital
        • Ta kontakt med:
      • Osaka, Osaka, Japan, 558-8558
      • Osaka, Osaka, Japan, 543-0042
        • Rekruttering
        • Osaka Keisatsu Hospital
        • Ta kontakt med:
      • Osaka, Osaka, Japan, 540-0006
        • Rekruttering
        • Osaka National Hospital
        • Ta kontakt med:
      • Sakai, Osaka, Japan, 590-0197
        • Har ikke rekruttert ennå
        • Kindai University Hopital
        • Ta kontakt med:
      • Suita, Osaka, Japan, 565-0871
        • Har ikke rekruttert ennå
        • The University of Osaka Hospital
        • Ta kontakt med:
    • Saitama
      • Hidaka, Saitama, Japan, 350-1298
        • Rekruttering
        • Saitama Medical University International Medical Center
        • Ta kontakt med:
      • Saitama, Saitama, Japan, 330-8553
        • Rekruttering
        • Japanese Red Cross Saitama Hospital
        • Ta kontakt med:
    • Tochigi
      • Mibu, Tochigi, Japan, 321-0293
        • Rekruttering
        • Dokkyo Medical University Hospital
        • Ta kontakt med:
      • Shimotsuke, Tochigi, Japan, 329-0498
        • Rekruttering
        • Jichi Medical University Hospital
        • Ta kontakt med:
    • Tokushima
      • Tokushima, Tokushima, Japan, 770-8503
        • Har ikke rekruttert ennå
        • Tokushima University Hospital
        • Ta kontakt med:
    • Tokyo
      • Adachi-ku, Tokyo, Japan, 123-8558
        • Har ikke rekruttert ennå
        • Tokyo Women's Medical University Adachi Medical Center
        • Ta kontakt med:
      • Bunkyō-Ku, Tokyo, Japan, 113-8519
        • Har ikke rekruttert ennå
        • Institute of Science Tokyo Hospital
        • Ta kontakt med:
      • Bunkyō-Ku, Tokyo, Japan, 113-8603
        • Har ikke rekruttert ennå
        • Nippon Medical School Hospital
        • Ta kontakt med:
      • Kodaira, Tokyo, Japan, 187-8510
        • Rekruttering
        • Showa General Hospital
        • Ta kontakt med:
      • Minato-Ku, Tokyo, Japan, 108-0073
        • Har ikke rekruttert ennå
        • Tokyo Saiseikai Central Hospital
        • Ta kontakt med:
      • Minato-Ku, Tokyo, Japan, 105-8471
        • Har ikke rekruttert ennå
        • The Jikei University Hspital
        • Ta kontakt med:
      • Mitaka, Tokyo, Japan, 181-8611
        • Rekruttering
        • Kyorin University Hospital
        • Ta kontakt med:
      • Shinjuku-Ku, Tokyo, Japan, 162-8666
        • Rekruttering
        • Tokyo Women's Medical University Hospital
        • Ta kontakt med:
      • Shinjuku-Ku, Tokyo, Japan, 160-0023
        • Rekruttering
        • Tokyo Medical University Hospital
        • Ta kontakt med:
      • Tama, Tokyo, Japan, 206-8512
        • Har ikke rekruttert ennå
        • Nippon Medical School Tamanagayama hospital
        • Ta kontakt med:
    • Yamanashi
      • Chūō, Yamanashi, Japan, 409-3898
        • Rekruttering
        • University of Yamanashi Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Clinically stable ischemic stroke or high-risk TIA (ABCD2 score >=4) between 24 hours and 3 years from onset at enrollment.
  2. Contrast-enhanced CT angiography (CTA) within 3 months prior to consent demonstrating 50-99% stenosis (WASID criteria) in a symptomatic intracranial artery: intracranial internal carotid artery, middle cerebral artery (M1/M2), anterior cerebral artery (A1), vertebral artery (V4), basilar artery, or posterior cerebral artery (P1).
  3. Fasting triglycerides (TG) 150-499 mg/dL, or non-fasting TG 175-499 mg/dL, measured within 4 weeks prior to consent.
  4. Men or women aged >=18 years at the time of consent.
  5. Ability to obtain written informed consent from the patient or a legally authorized representative.

Exclusion Criteria:

  1. Patients with intracranial arterial stenosis due to non-atherosclerotic disorders (e.g., vasculitis, moyamoya disease, intracranial arterial dissection).
  2. Patients with >=70% stenosis of the extracranial carotid artery (NASCET criteria).
  3. Patients with neurological deterioration within 24 hours prior to enrollment.
  4. Patients who received intravenous thrombolysis or mechanical thrombectomy within 24 hours prior to enrollment.
  5. Patients scheduled to undergo revascularization procedures (percutaneous transluminal angioplasty, stent placement, carotid endarterectomy, or cerebral bypass surgery).
  6. Patients who meet any contraindication to pemafibrate, including:

(1) History of hypersensitivity to pemafibrate; (2) Severe hepatic impairment or liver cirrhosis classified as Child-Pugh B or C; (3) Cholelithiasis; (4) Pregnancy or suspected pregnancy; (5) Concomitant use of cyclosporine or rifampin. 7. Patients who have taken pemafibrate or any fibrate within 12 weeks prior to consent.

8. Patients with contraindications to iodinated contrast media. 9. Patients on dialysis. 10. Patients with a history of pancreatitis attributable to hypertriglyceridemia.

11. Patients with severe systemic comorbidities with an expected survival <12 months.

12. Patients who may be pregnant, are pregnant, or are breastfeeding. 13. Any other condition for which the principal or sub-investigator judges participation to be inappropriate.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Pemafibrate group
Participants in this arm will receive pemafibrate in addition to standard medical therapy.
Legemiddel: Pemafibrate
Participants in this arm will receive pemafibrate in addition to standard medical therapy.
Ingen inngripen: Non-pemafibrate group
Participants in this arm will receive standard medical therapy without pemafibrate.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression in intracranial arterial stenosis on CTA at 12 months from enrollment (progression vs. no progression [no change or improvement])
Tidsramme: Baseline and 12 months

Stenosis is assessed by the WASID method; progression is defined as an absolute increase of >=10 percentage points in percent stenosis or the development of occlusion, stability as a change of <10 percentage points in either direction, and improvement as an absolute decrease of >=10 percentage points.

If, during follow-up, emergency or unplanned revascularization (mechanical thrombectomy, percutaneous transluminal angioplasty, stent placement, or bypass surgery) is performed for the target culprit vessel lesion evaluated at registration in relation to progression or occlusion of that lesion, the case will be classified as "progression" regardless of the availability of CTA findings at 12 months.
Baseline and 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Key secondary endpoint (supplementary analyses of the primary endpoint): Change in intracranial arterial stenosis on CTA at 12 months from enrollment (three categories: progression, no change, improvement)
Tidsramme: Baseline and 12 months
Baseline and 12 months
Key secondary endpoint (supplementary analyses of the primary endpoint): Improvement in intracranial arterial stenosis on CTA at 12 months from enrollment (improvement vs. no improvement [progression or no change])
Tidsramme: Baseline and 12 months
Baseline and 12 months
Change in percent stenosis by the WASID method
Tidsramme: Baseline and 12 months
Baseline and 12 months
Proportion of intracranial arterial stenosis progression/improvement per the TOSS and TOSS-2 criteria
Tidsramme: Baseline and 12 months
Baseline and 12 months
Proportion of intracranial arterial stenosis progression/improvement per the Wong KS criteria
Tidsramme: Baseline and 12 months
Baseline and 12 months
All-cause mortality
Tidsramme: From enrollment to the end of treatment at 12 months
From enrollment to the end of treatment at 12 months
Change in Fazekas scale on brain MRI
Tidsramme: Baseline and 12 months
Baseline and 12 months
Change in number of cerebral microbleeds on brain MRI
Tidsramme: Baseline and 12 months
Baseline and 12 months
Change in total cerebral small vessel disease score on brain MRI
Tidsramme: Baseline and 12 months
Baseline and 12 months
Changes in blood biomarkers
Tidsramme: Baseline, 3 months, 6 months, and 12 months
Complete blood count; fasting TG, HDL-C, LDL-C, RLP-C; apolipoprotein C-III; lipoprotein(a); fasting plasma glucose; HbA1c; AST, ALT, gamma-GTP; creatinine, eGFR; CK; CRP, high-sensitivity CRP; IL-6; total homocysteine; PT-INR; APTT; fibrinogen; D-dimer
Baseline, 3 months, 6 months, and 12 months
Safety: occurrence of adverse events and illnesses
Tidsramme: From enrollment to the end of treatment at 12 months
From enrollment to the end of treatment at 12 months
Activities of daily living by mRS score (mRS 0-1, 0-2, and 0-3 proportions, and the overall mRS score distribution)
Tidsramme: Baseline and 12 months
The modified Rankin Scale (mRS) ranges from 0 to 6, with higher scores indicating greater disability or death; therefore, higher scores indicate a worse outcome.
Baseline and 12 months
Changes in ankle-brachial index (ABI)
Tidsramme: Baseline and 12 months
Baseline and 12 months
Change in cardio-ankle vascular index (CAVI)
Tidsramme: Baseline and 12 months
Baseline and 12 months
Change in pulse wave velocity (PWV)
Tidsramme: Baseline and 12 months
Baseline and 12 months
Major cardiovascular events (MACE)
Tidsramme: From enrollment to the end of treatment at 12 months

The following individual events and their composite:

Ischemic stroke (fatal, nonfatal), TIA, intracranial hemorrhage (fatal, nonfatal), any stroke (ischemic stroke, TIA, intracranial hemorrhage), emergency or unplanned revascularization procedures, including mechanical thrombectomy, percutaneous transluminal angioplasty, stent placement, or bypass surgery Myocardial infarction (fatal, nonfatal), any coronary artery disease event (myocardial infarction, or angina treated with PCI or CABG) Symptomatic peripheral artery disease (with intermittent claudication, ulceration, or gangrene; or requiring revascularization) Vascular death
From enrollment to the end of treatment at 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Tokyo Women's Medical University

Samarbeidspartnere

Kowa Company, Ltd.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. mai 2026

Primær fullføring (Antatt)

31. mars 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

20. april 2026

Først innsendt som oppfylte QC-kriteriene

25. april 2026

Først lagt ut (Faktiske)

1. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • JIHS-C-005243-00

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere